Highly motivated individual with many years industrial synthetic biology, innovate RD, Strategy &BD and OMD of solid tumor CART experience. Currently, as founder and CEO charges KAEDI Biotherapeutics strategies executive. KAEDI has closed series preA and A+ financing and is initiating the series B financing. KAEDI has multiple first-in-class CAR-T pipelines for solid tumor indications such as gastric cancer, pancreatic cancer, HCC , GBM and etc. KAEDI has filled 30 patents and 15 was approved. Hi ALL We are planning how to open up the European and American markets through cooperative development or licensing of partial rights to our products. Are you interested? please contact paul.dai@kaedibio.com. We will follow market rules. If BD is successful, we will pay a commission fee of 3-5% of the actual amount received, thanks
Nanjing Kaedi Biotherapeutics
-
Founder And CeoNanjing Kaedi Biotherapeutics Sep 2016 - PresentKAEDI is a clinical stage biopharmaceutical company. The company is committed to research and development of CAR-T and CAR-NK for the treatment of malignant tumors. Depending on our advanced synthetic biology technology platform-KD-SmCAR, KAEDI has successfully developed four innovative pipelines for malignant tumor therapy, including next generation CAR-T. More than 30 of patents have been filled and 15 was approval. The indications include CRC, HCC and GBM. Pre-clinical research results of KD-025 CAR-T pipeline have been published in the international journals such as "Journal for ImmunoTherapy of Cancer" and "Cancer Immunology Research". KD-025 CAR-T POC clinical trials are currently ongoing well with the low dose administration. and IND was approval on Mar 2023.
-
Director And Senior ScientitstGenscript Apr 2013 - Aug 2016Piscataway, Nj, UsOversee and manage daily operations, R&D and technical support -
Postdoctoral ResearcherUniversity Of Illinois Chicago Oct 2012 - Apr 2013Chicago, Il, UsCharge the project investigation of ovary cancer oncogenes and execute -
Postdoctoral ScholarUniversity Of California, Riverside Jun 2009 - Sep 2012Riverside, Ca, UsMajor: neuron development and GPCR funcation. Genetic manipulation is the key tool to cKO the taget genes and further investigate the function. -
Postdoctoral Research AssociateUniversity Of Nebraska-Lincoln May 2008 - Jun 2009Lincoln, Ne, UsMy researches mainly focuses on CD4 T cell immunity and miRNA function research.
Paul Dai Skills
Paul Dai Education Details
-
University Of Chinese Academy Of SciencesZoology/Animal Biology -
Nanchang UniversityGeneral
Frequently Asked Questions about Paul Dai
What company does Paul Dai work for?
Paul Dai works for Nanjing Kaedi Biotherapeutics
What is Paul Dai's role at the current company?
Paul Dai's current role is Founder and CEO at KAEDI Biotherapeutics.
What schools did Paul Dai attend?
Paul Dai attended University Of Chinese Academy Of Sciences, Nanchang University.
What are some of Paul Dai's interests?
Paul Dai has interest in Sports Etc, Culture, Management Training, Fishing, New Technologies, Military, Digital Photography, Investment, History.
What skills is Paul Dai known for?
Paul Dai has skills like Cell Culture, Cell Biology, Life Sciences, Molecular Biology, Genetics, Immunohistochemistry, Biotechnology, R&d, Immunology, Biochemistry, Operation And Management, Cell Therapy.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial